Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- EFCC re-arraigns ex-Skye Bank board chairman for alleged N15.6bn fraud
- CDCFIB warns against fake recruitment information, threatens prosecution
- A Source of Mysterious Repeating Radio Signals From Space Has Been Identified
- 6 out of 7: How APC swept Ekiti gov, 5 bye-elections, lost Rivers to PDP
- US to phase out HIV/AIDS funding for South Africa over policy disputes
- ‘Slug sleuth’ farmers in England help develop prediction tool to cut back on pesticide use | Business
- Rothesay County Championship: Kiran Carlson helps Glamorgan to a long-awaited win over Surrey | Cricket News
- National Portrait Gallery display withdrawn after Churchill row
